Fred A. Middleton Purchases 87,744 Shares of CalciMedica, Inc. (NASDAQ:CALC) Stock

Posted by Donna Armstrong on Nov 7th, 2024

CalciMedica, Inc. (NASDAQ:CALC – Get Free Report) Director Fred A. Middleton purchased 87,744 shares of the business’s stock in a transaction on Friday, November 1st. The stock was purchased at an average cost of $3.75 per share, with a total value of $329,040.00. Following the completion of the acquisition, the director now owns 814,300 shares in the company, valued at approximately $3,053,625. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

CalciMedica Stock Performance

CalciMedica stock opened at $3.50 on Thursday. CalciMedica, Inc. has a fifty-two week low of $2.68 and a fifty-two week high of $8.38. The firm’s fifty day moving average price is $4.23 and its 200-day moving average price is $4.63.

CalciMedica (NASDAQ:CALC – Get Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.03. On average, equities analysts forecast that CalciMedica, Inc. will post -2.21 earnings per share for the current year.

Wall Street Analyst Weigh In

CALC has been the subject of several research analyst reports. Oppenheimer lifted their price objective on CalciMedica from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday, July 10th. HC Wainwright dropped their price target on CalciMedica from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Monday.

Read Our Latest Report on CALC

Institutional Trading of CalciMedica

An institutional investor recently raised its position in CalciMedica stock. Atria Investments Inc grew its holdings in shares of CalciMedica, Inc. (NASDAQ:CALC – Free Report) by 136.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 26,503 shares of the company’s stock after acquiring an additional 15,296 shares during the quarter. Atria Investments Inc owned 0.25% of CalciMedica worth $117,000 at the end of the most recent quarter.

CalciMedica Company Profile

(Get Free Report)

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.